Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimer’s Disease

阿尔茨海默病遗传亚型的运动、视觉和嗅觉变化

基本信息

批准号：
10549307
负责人：
JOHN M RINGMAN
金额：
$ 82.08万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-15 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10549307
关键词：
Aging Alzheimer&apos s Disease Amyloid Anatomy Anosmia Biological Markers Blood Vessels Blood capillaries CNS degeneration Cessation of life Clinical Cognition Contrast Sensitivity Deposition Deterioration Development Diagnosis Differential Diagnosis Diffusion Diffusion Magnetic Resonance Imaging Disease Management Disease Progression Equilibrium Esthesia Etiology Evaluation Event Future Gait Gait abnormality Genetic Glaucoma Human Image Knowledge Late Onset Alzheimer Disease Lateral Geniculate Body Macular degeneration Measurable Measures Memory Mexican Modeling Motor Motor Cortex Musculoskeletal System Mutation Nature Odors Olfactory Pathways Optic Nerve Optics Pathology Pennsylvania Peripheral Peripheral Nervous System Diseases Persons Photophobia Physiologic pulse Polyneuropathy Positron-Emission Tomography Prognosis Protocols documentation Radiation Reading Resolution Retina Risk Sensory Smell Perception Speed Standardization Structure Symptoms Testing Thick Thinking Thinness United States National Institutes of Health Universities Vision Visual Visual Acuity Visual Pathways Visual System autosomal dominant Alzheimer&apos s disease autosome biomarker identification clinically relevant comorbidity connectome density disability falls ganglion cell in vivo imaging motor deficit mutational status pre-clinical presenilin-1 retinal nerve fiber layer senescence tau Proteins therapeutic target walking speed

项目摘要

Title: Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimer's Disease Though changes in cognition are the most salient features of Alzheimer's disease (AD), subtle changes in sensation and motor function occur early in the course of AD and might serve as biomarkers and provide clues as to the cascade of events leading to progressive disability. We will perform baseline (n = 135) and 3-year f/u evaluations (n = 60) in an ongoing study using the Human Connectome Project (HCP) protocol of persons of Mexican descent with and at-risk for autosomal dominant (ADAD) and late-onset AD (LOAD) in order to achieve the following specific aims: Specific Aim 1a) To define the underlying cause and mechanisms of gait abnormalities in ADAD and LOAD, we will characterize motor and gait function using the NIH toolbox, the HCP imaging protocol, and tau PET imaging with flortaucipir. Specific Aim 1b) To characterize the onset and course of cortical hyperexcitability in ADAD and LOAD using single-pulse TMS. Specific Aim 2a) To characterize clinically relevant visual deficits in persons with and at-risk for ADAD and LOAD using standardized functional measures including logMAR based visual acuity, contrast sensitivity, as well as low and high contrast reading speed. Specific Aim 2b) To define the underlying etiology of visual deficits by performing high-resolution, in- vivo imaging of central and peripheral visual pathway structures including retinal nerve fiber layer (RNFL), retinal capillary density, volume of optic nerve/chiasm and the lateral geniculate nucleus (LGN) and connectivity using the HCP. Specific Aim 3) To characterize deficits in olfaction occurring in persons with and at-risk for ADAD and LOAD, we will assess olfaction using the University of Pennsylvania Smell Identification Test (UPSIT) and relate this to tau pathology and connectivity in the olfactory system measured using the HCP. Comprehensive characterization of motor and sensory changes in ADAD and LOAD could identify biomarkers for diagnosis, prognosis, and therapeutics targets in the management of the disease. 1

标题：阿尔茨海默病遗传亚型的运动、视觉和嗅觉变化尽管认知变化是阿尔茨海默病 (AD) 最显着的特征，但微妙的变化感觉和运动功能的变化发生在 AD 病程的早期，可能是生物标志物并提供导致渐进性残疾的一系列事件的线索。我们将在一项正在进行的研究中使用人类进行基线 (n = 135) 和 3 年 f/u 评估 (n = 60) 连接组项目 (HCP) 墨西哥裔常染色体病患者和有常染色体病风险的人的协议显性（ADAD）和迟发性AD（LOAD），以实现以下具体目标：具体目标 1a) 明确 ADAD 和 ADAD 步态异常的根本原因和机制 LOAD，我们将使用 NIH 工具箱、HCP 成像协议来表征运动和步态功能，以及使用 flaucipir 进行 tau PET 成像。具体目标 1b) 表征 ADAD 和 LOAD 中皮质过度兴奋的发作和过程使用单脉冲 TMS。具体目标 2a) 描述 ADAD 患者和高危人群的临床相关视觉缺陷特征和 LOAD 使用标准化功能测量，包括基于 logMAR 的视力、对比度灵敏度以及低对比度和高对比度读取速度。具体目标 2b) 通过执行高分辨率、in- 包括视网膜神经纤维层在内的中央和周围视觉通路结构的体内成像 (RNFL)、视网膜毛细血管密度、视神经/交叉体积和外侧膝状核 (LGN) 以及使用 HCP 的连接。具体目标 3) 描述患有 ADAD 和有 ADAD 风险的人中发生的嗅觉缺陷负载，我们将使用宾夕法尼亚大学气味识别测试 (UPSIT) 评估嗅觉并将其与使用 HCP 测量的嗅觉系统中的 tau 病理学和连接性联系起来。 ADAD 和 LOAD 中运动和感觉变化的综合表征可以识别用于疾病管理中诊断、预后和治疗目标的生物标志物。 1